TherapeuticsMD (TXMD) Q1 2025 earnings summary

Executive summary

• Transitioned to a pharmaceutical royalty company in December 2022, collecting royalties from licensed products after divesting commercial operations.

• Main revenue sources are royalties from Mayne Pharma, Theramex, and Knight for products IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins.

• License revenue increased 25.8% year-over-year to $393K in Q1 2025, primarily from the Mayne License Agreement.

• Net loss from continuing operations was $636K ($0.06 per share) in Q1 2025, improved from $809K ($0.07 per share) in Q1 2024.

• Operating expenses decreased 13.1% year-over-year to $1.26M, reflecting cost efficiencies as a royalty-based business.

Financial highlights

• License revenue for Q1 2025 was $393K, up from $313K in Q1 2024, driven by increased sales of licensed products.

• Net loss for Q1 2025 was $653K ($0.06 per share), compared to $734K ($0.06 per share) in Q1 2024.

• Cash and cash equivalents as of March 31, 2025, totaled $5.7M, up from $5.1M at year-end 2024.

• Net cash provided by operating activities was $699K in Q1 2025, compared to net cash used of $229K in Q1 2024.

• No new equity issued in Q1 2025; prior private placements in 2023 raised $3.15M.

Outlook and guidance

• Substantial doubt exists about the ability to continue as a going concern for the next twelve months due to unresolved disputes, potential adverse outcomes, and capital market uncertainties.

• May seek additional equity or debt financing; failure to secure funding may require curtailing operations or asset sales.

• Actively evaluating strategic alternatives, including potential acquisition, merger, asset sale, or other business combinations; no timetable set.

• No further updates on strategic review will be provided unless deemed appropriate.